← FDA DRUG APPROVALS

FDA ANDA · ANDA210440

DIMETHYL FUMARATE

Sponsor: ALKEM LABS LTD

APPLICATION
ANDA210440
TYPE
ANDA
ORIGINAL APPROVAL
2020-09-24
LATEST ACTION
2024-10-11
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

DIMETHYL FUMARATEPrescription
DIMETHYL FUMARATE 120MG · CAPSULE, DELAYED RELEASE · ORAL
DIMETHYL FUMARATEPrescription
DIMETHYL FUMARATE 240MG · CAPSULE, DELAYED RELEASE · ORAL

Approval history

2024-10-11Labeling · Supplement 7 · standardAP
2024-10-11Labeling · Supplement 5 · standardAP
2024-10-11Labeling · Supplement 8 · standardAP
2024-10-11Labeling · Supplement 10 · standardAP
2024-10-11Labeling · Supplement 4 · standardAP
2024-10-11Labeling · Supplement 2 · standardAP
2020-09-24UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →